IBD0333 / SunHo BioPharma - LARVOL DELTA

Preclinical characterization of IBD0333, a novel CD24×4-1BB bispecific antibody with tumor-dependent agonistic activity for cancer immunotherapy. (PubMed, Antib Ther) - "IBD0333 is a tumor-conditionally activated anti-CD24×4-1BB bsAb that demonstrates potent antitumor efficacy along with a favorable safety and pharmacokinetic profile. These findings support its further clinical development."

Journal • Preclinical • Oncology • CD24

Preclinical evaluation of a potential FIC 4-1BB/CD24 bispecific antibody IBD0333 (AACR 2024) - "IBD0333 is a clinical stage, potential first-in-class, 4-1BB/CD24 bsAb that simultaneously stimulates both innate and adaptive immunity to achieve strong synergistic effects with reduced hepatotoxicity. The IND approvals from the FDA and the NMPA have been obtained and the Phase I clinical trial of IBD0333 in locally advanced/metastatic solid tumors or non-Hodgkin's lymphoma is currently on-going."

Bispecific • Preclinical • Breast Cancer • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Solid Tumor • CD24 • CD8 • IL2

A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1/2 | N=48 | Recruiting | Sponsor: SUNHO（China）BioPharmaceutical CO., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1/2 | N=48 | Not yet recruiting | Sponsor: SUNHO（China）BioPharmaceutical CO., Ltd.

Metastases • New P1/2 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor